Q1 2023 Holdings
Filed 2023-05-15 | 74 holdings | $303.0M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Chinook Therapeutics Inc(290A) | COM | 16961L106 | $22.6M | 976,021 | 7.5% |
| Madrigal Pharmaceuticals Inc(MDGL) | COM | 558868105 | $22.5M | 93,000 | 7.4% |
| Spdr S&P 500 ETF Trtr Unit(SPY)Call | TR UNIT | 78462F103 | $18.4M | 45,000 | 6.1% |
| Prometheus Biosciences Inc | COM | 74349U108 | $16.1M | 150,000 | 5.3% |
| Merck & Co Inc(MRK) | COM | 58933Y105 | $12.8M | 120,000 | 4.2% |
| Viking Therapeutics Inc(VKTX) | COM | 92686J106 | $10.4M | 622,249 | 3.4% |
| Cymabay Therapeutics Inc(CBAYUSD) | COM | 23257D103 | $9.4M | 1,083,118 | 3.1% |
| Cerevel Therapeutics Hldng I(CERE1EUR) | COM | 15678U128 | $9.3M | 380,000 | 3.1% |
| Verona Pharma PLC(VRNA) | SPONSORED ADR | 925050106 | $9.1M | 452,821 | 3.0% |
| Ventyx Biosciences Inc(VTYX) | COM | 92332V107 | $8.7M | 260,008 | 2.9% |
| Cytokinetics Inc(CYTK) | COM NEW | 23282W605 | $7.8M | 221,463 | 2.6% |
| Establishment Labs Hldgs Inc(ESTA) | COM | G31249108 | $7.7M | 113,224 | 2.5% |
| Bridgebio Pharma Inc | NOTE 2.500% 3/1 | 10806XAB8 | $7.4M | $10,000,000 | 2.4% |
| Bridgebio Pharma Inc | NOTE 2.250% 2/0 | 10806XAD4 | $7.1M | $11,000,000 | 2.4% |
| Astria Therapeutics Inc(CATBUSD) | COM | 04635X102 | $7.0M | 529,369 | 2.3% |
| Bridgebio Pharma Inc(BBIO)Put | COM | 10806X102 | $6.5M | 389,800 | 2.1% |
| Bellus Health Inc New(BLU) | COM NEW | 07987C204 | $6.3M | 881,329 | 2.1% |
| Arcellx Inc(ACLX) | COMMON STOCK | 03940C100 | $6.2M | 202,834 | 2.1% |
| Moderna Inc(MRNA)Call | COM | 60770K107 | $5.4M | 35,000 | 1.8% |
| Bridgebio Pharma Inc(BBIO) | COM | 10806X102 | $5.3M | 320,000 | 1.8% |
| Morphic Hldg Inc | COM | 61775R105 | $5.1M | 135,863 | 1.7% |
| Kura Oncology Inc(KURA) | COM | 50127T109 | $4.4M | 357,287 | 1.4% |
| Inozyme Pharma Inc | COM | 45790W108 | $4.3M | 751,796 | 1.4% |
| Ascendis Pharma A/S(ASND) | SPONSORED ADR | 04351P101 | $4.3M | 40,000 | 1.4% |
| Astrazeneca PLC(AZN) | SPONSORED ADR | 046353108 | $4.2M | 60,000 | 1.4% |
| Seagen Inc(SGENUSD) | COM | 81181C104 | $4.0M | 20,000 | 1.3% |
| Argenx SE(ARGX) | SPONSORED ADR | 04016X101 | $4.0M | 10,750 | 1.3% |
| Astrazeneca PLC(AZN)Call | SPONSORED ADR | 046353108 | $3.5M | 50,000 | 1.1% |
| Xenon Pharmaceuticals Inc(XENE) | COM | 98420N105 | $3.2M | 90,000 | 1.1% |
| 89Bio Inc(ETNBGBP) | COM | 282559103 | $3.0M | 200,000 | 1.0% |
| Esperion Therapeutics Inc NE | NOTE 4.000%11/1 | 29664WAB1 | $3.0M | $7,500,000 | 1.0% |
| Centessa Pharmaceuticals PLC(CNTA) | SPONSORED ADR | 152309100 | $2.6M | 684,127 | 0.9% |
| Viridian Therapeutics Inc(VRDN)Call | COM | 92790C104 | $2.6M | 100,500 | 0.8% |
| Lantheus Hldgs Inc(LNTH) | COM | 516544103 | $2.5M | 30,244 | 0.8% |
| Biomarin Pharmaceutical Inc(BMRN) | COM | 09061G101 | $2.4M | 25,000 | 0.8% |
| Novavax Inc(NVAX)Put | COM NEW | 670002401 | $2.4M | 346,800 | 0.8% |
| Vaxcyte Inc(PCVX) | COM | 92243G108 | $2.3M | 62,223 | 0.8% |
| Apellis Pharmaceuticals Inc(APLS) | COM | 03753U106 | $2.3M | 35,000 | 0.8% |
| Mirum Pharmaceuticals Inc(MIRM) | COM | 604749101 | $2.3M | 95,000 | 0.8% |
| Karuna Therapeutics Inc | COM | 48576A100 | $2.3M | 12,500 | 0.7% |
| Horizon Therapeutics PUB L | SHS | G46188101 | $2.2M | 20,000 | 0.7% |
| Alpine Immune Sciences Inc(NVLSEUR) | COM | 02083G100 | $1.9M | 247,891 | 0.6% |
| Celldex Therapeutics Inc New(CLDX) | COM NEW | 15117B202 | $1.8M | 50,000 | 0.6% |
| Karyopharm Therapeutics Inc(KPTIEUR) | COM | 48576U106 | $1.8M | 460,979 | 0.6% |
| Kalvista Pharmaceuticals Inc(KALV) | COM | 483497103 | $1.6M | 208,292 | 0.5% |
| Viking Therapeutics Inc(VKTX)Put | COM | 92686J106 | $1.6M | 93,900 | 0.5% |
| Vincerx Pharma Inc | COM NEW | 92731L106 | $1.6M | 1,492,771 | 0.5% |
| Cogent Biosciences Inc(COGT) | COM | 19240Q201 | $1.5M | 143,064 | 0.5% |
| Precigen Inc | NOTE 3.500% 7/0 | 46122TAA0 | $1.5M | $1,500,000 | 0.5% |
| Nurix Therapeutics Inc(NRIX) | COM | 67080M103 | $1.3M | 150,000 | 0.4% |